Researchers describe novel mechanism of HIV-1 spread by dendritic cells

NewsGuard 100/100 Score

A new understanding of the initial interactions of human immunodeficiency virus type 1 (HIV-1) and dendritic cells is described by Boston University School of Medicine (BUSM) researchers in a study currently featured in the Proceedings of the National Academy of Sciences (PNAS). With over 2.5 million new HIV infections diagnosed annually and earlier detection becoming more common, better understanding of early virus-host interactions could have a great impact on future research and drug therapy.

In this study, the researchers describe a novel mechanism of HIV-1 spread by dendritic cells. These cells, which are present at the body's mucosal surfaces, are the focus of research because they are among the first cells to encounter HIV-1 and trigger the immune system. While previous work has focused on the HIV-1 envelope glycoprotein method of interactions, this research details the role of a molecule called GM3, which arises from the host itself and is used by the virus for attachment and spread.

Since this virus invasion method depends on the molecules originating from the host, "it is a stealth entry mechanism, likely not detected by the cell, so HIV can spread quickly," says Dr. Rahm Gummuluru, associate professor in the department of microbiology at BUSM and senior author of the study.

Despite the cleverness of the virus, this unique contact between HIV-1 and dendritic cells may offer a new direction for anti-viral therapies. "Resistance to therapy, which often challenges physicians, is unlikely to occur in drugs that target this interaction, as these drugs would have the benefit of acting on the host, instead of the virus," Gummuluru. Further research in this field may identify specific targets and offer hope for preventing HIV infections.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Interferon-beta deficiency alters brain response in neuroHIV mouse model